0.8025
price down icon2.73%   -0.0225
after-market Dopo l'orario di chiusura: .81 0.0075 +0.93%
loading
Precedente Chiudi:
$0.825
Aprire:
$0.83
Volume 24 ore:
871.46K
Relative Volume:
1.41
Capitalizzazione di mercato:
$32.10M
Reddito:
-
Utile/perdita netta:
$-35.58M
Rapporto P/E:
-0.3028
EPS:
-2.65
Flusso di cassa netto:
$-42.82M
1 W Prestazione:
-12.45%
1M Prestazione:
-22.09%
6M Prestazione:
-47.20%
1 anno Prestazione:
-35.80%
Intervallo 1D:
Value
$0.8005
$0.8399
Intervallo di 1 settimana:
Value
$0.8005
$0.92
Portata 52W:
Value
$0.8005
$3.02

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name
Nome
Iterum Therapeutics Plc
Name
Telefono
(872) 225-6077
Name
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Name
Dipendente
9
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-07
Name
Ultimi documenti SEC
Name
ITRM's Discussions on Twitter

Confronta ITRM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ITRM
Iterum Therapeutics Plc
0.8025 33.00M 0 -35.58M -42.82M -2.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-05-28 Aggiornamento Gabelli & Co Sell → Hold
2021-03-15 Aggiornamento H.C. Wainwright Neutral → Buy
2020-06-02 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-01-21 Downgrade Gabelli & Co Buy → Sell
2019-12-11 Downgrade SVB Leerink Outperform → Mkt Perform
2019-06-21 Iniziato H.C. Wainwright Buy
Mostra tutto

Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie

pulisher
Jul 25, 2025

Iterum Therapeutics plc Stock Analysis and ForecastFree Stock Market Trend Analysis - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Is Iterum Therapeutics plc a good long term investmentSuperior risk-adjusted returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Iterum Therapeutics plc stock priceConsistently exceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Iterum Therapeutics Plc (ITRM) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Iterum Therapeutics plc stockHigh-profit capital plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 15, 2025

Why Iterum Therapeutics plc stock attracts strong analyst attentionMassive Profit Potential - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Iterum Therapeutics plc stock price move sharplyWatchlist Winner Update - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Iterum Therapeutics plc stock performs during market volatilityFree Access to Investment Community - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

OneDigital Investment Advisors LLC Invests $124,000 in Iterum Therapeutics PLC (NASDAQ:ITRM) - Defense World

Jul 14, 2025
pulisher
Jul 08, 2025

Iterum Therapeutics (NASDAQ:ITRM) Trading Down 4.2% – Here’s What Happened - Defense World

Jul 08, 2025
pulisher
Jul 05, 2025

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛

Jul 05, 2025
pulisher
Jun 30, 2025

Iterum Strengthens Launch Strategy: 30-Year Pharma Veteran Christine Coyne to Lead ORLYNVAH Commercialization - Stock Titan

Jun 30, 2025
pulisher
Jun 30, 2025

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Yahoo Finance

Jun 30, 2025
pulisher
Jun 29, 2025

Certain Options of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener

Jun 29, 2025
pulisher
Jun 29, 2025

Certain Ordinary Shares of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener

Jun 29, 2025
pulisher
Jun 25, 2025

Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Resul - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Results | ITRM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

New Antibiotic Shows Promise Against Drug-Resistant UTIs: NEJM Evidence Reveals 9.2% Multi-Resistance Rate - Stock Titan

Jun 25, 2025
pulisher
Jun 17, 2025

Transcript : Iterum Therapeutics plcSpecial Call - MarketScreener

Jun 17, 2025
pulisher
Jun 14, 2025

Research Analysts Set Expectations for ITRM FY2026 Earnings - Defense World

Jun 14, 2025
pulisher
Jun 14, 2025

Two Sigma Investments LP Invests $45,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships - pharmaphorum

Jun 13, 2025
pulisher
Jun 12, 2025

Citadel Advisors LLC Acquires Shares of 21,207 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Iterum Therapeutics (ITRM) Partners with EVERSANA for U.S. Launc - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Iterum Therapeutics announces partnership with EVERSANA - PharmaLive

Jun 11, 2025
pulisher
Jun 11, 2025

Iterum Therapeutics inks deal for ORLYNVAH commercialization By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Iterum Therapeutics inks deal for ORLYNVAH commercialization - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Iterum Therapeutics Announces Partnership for Commercialization Services - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History - Stock Titan

Jun 11, 2025
pulisher
May 19, 2025

Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus

May 19, 2025

Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):